Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| IDEAYA Biosciences, Inc.IDYA · Entity 4069 | Chief Financial Officer | August 29, 2023 | August 31, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
IDEAYA Biosciences, Inc.
Report date August 29, 2023 · Filed August 31, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 9,303 |
Reported balance
After 2023-08-29 transaction · row 1
1 source rowRow 1 · 2023-08-29 · Sale · Disposed 5,000 · Balance 9,303 F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. F2: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023.
F2: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| August 29, 2023 Filed Aug 31, 2023 17:49 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 5,000 | $28.87 | $144,351.50 |
DisclosureSEC source: 0001610717-23-000251 · form4.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,303 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $28.83 to $29.02, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 21, 2023 Filed Aug 23, 2023 18:31 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 978 | $26.40 | $25,819.49 |
DisclosureSEC source: 0001610717-23-000234 · form4.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,303 F1 · kind: The transaction reported herein was effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $26.38 to $26.4175, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 18, 2023 Filed Aug 18, 2023 18:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 3,822 | $26.38 | $100,820.16 |
DisclosureSEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 3 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 15,281 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $26.37 to $26.415, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 100 | $26.40 | $2,640.00 |
DisclosureSEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 2 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,103 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. Read SEC document |
| August 16, 2023 Filed Aug 18, 2023 18:33 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 100 | $26.45 | $2,645.00 |
DisclosureSEC source: 0001610717-23-000233 · form4.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,203 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. Read SEC document |
| August 09, 2023 Filed Aug 11, 2023 19:21 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,500 | $25.05 | $62,613.25 |
DisclosureSEC source: 0001610717-23-000225 · form4.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,303 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan, adopted on March 27, 2023. F2 · price: This transaction was executed in multiple trades in prices ranging from $25.00 to $25.105, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 13:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 8,000 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001610717-23-000009 · form4.xml · derivative · entry 2 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 129,832 Underlying: Common Stock · 8,000 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The shares subject to the option are fully vested and exercisable. Read SEC document |
| April 13, 2023 Filed Apr 14, 2023 13:20 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 8,000 | $4.62 | $36,960.00 |
DisclosureSEC source: 0001610717-23-000009 · form4.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,803 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · balance_after: The amount reported herein has been adjusted to correct an error in Column 5 of Table I in a Form 4 previously filed on April 14, 2022. Read SEC document |
| February 24, 2023 Filed Feb 28, 2023 17:01 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 140,000 | $0.00 Strike: $17.04 | $0.00 |
DisclosureSEC source: 0001567619-23-003947 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,000 Underlying: Common Stock · 140,000 shares Expires 2033-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2023 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 01, 2022 Filed Mar 2, 2022 19:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 92,500 | $0.00 Strike: $12.86 | $0.00 |
DisclosureSEC source: 0001567619-22-006126 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,500 Underlying: Common Stock · 92,500 shares Expires 2032-02-29 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2022 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| September 07, 2021 Filed Sep 9, 2021 17:41 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,500 | $27.42 | $68,542.50 |
DisclosureSEC source: 0001567619-21-016924 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,944 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $27.37 to $27.57, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| May 28, 2021 Filed Apr 14, 2022 16:10 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantCommon Stock | 859 | $11.36 | $9,762.11 |
DisclosureSEC source: 0001567619-22-008545 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,803 F1 · shares: Acquired pursuant to Issuer's Employee Stock Purchase Plan. Read SEC document |
| February 24, 2021 Filed Feb 26, 2021 19:07 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $19.52 | $0.00 |
DisclosureSEC source: 0001567619-21-005111 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2031-02-23 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2021 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| December 11, 2020 Filed Dec 15, 2020 16:15 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | OtherCommon Stock | 444 | $0.00 | $0.00 |
DisclosureSEC source: 0001567619-20-021089 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,444 F1 · kind: Pro rata in-kind distribution from 5AM Partners IV, LLC for no consideration. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 3,100 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-20-012462 · doc1.xml · derivative · entry 4 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 137,832 Underlying: Common Stock · 3,100 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 600 | $19.95 | $11,968.02 |
DisclosureSEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 3 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades in prices ranging from $19.83 to $19.97, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | SaleCommon Stock | 2,500 | $17.50 | $43,748.75 |
DisclosureSEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 2 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,600 F1 · kind: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades in prices ranging from $17.48 to $17.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote. Read SEC document |
| June 17, 2020 Filed Jun 19, 2020 19:46 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 3,100 | $4.62 | $14,322.00 |
DisclosureSEC source: 0001567619-20-012462 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,100 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 16:06 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 5,000 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-20-007287 · doc1.xml · derivative · entry 4 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 140,932 Underlying: Common Stock · 5,000 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| March 30, 2020 Filed Apr 1, 2020 16:06 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 5,000 | $4.62 | $23,100.00 |
DisclosureSEC source: 0001567619-20-007287 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 21, 2020 Filed Feb 25, 2020 16:05 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | GrantStock Option (right to buy) · Derivative | 80,000 | $0.00 Strike: $6.92 | $0.00 |
DisclosureSEC source: 0001567619-20-004806 · doc1.xml · derivative · entry 1 Stone Paul A. · CIK 0001777511 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from January 1, 2020 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionStock Option (right to buy) · Derivative | 10,000 | $0.00 Strike: $4.62 | $0.00 |
DisclosureSEC source: 0001567619-19-015342 · doc1.xml · derivative · entry 4 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,932 Underlying: Common Stock · 10,000 shares Expires 2028-06-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to the option vest on the first anniversary measured from May 2, 2018 (the "Vesting Commencement Date"), and 1/48th of the total number of shares vest monthly thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date. Read SEC document |
| July 26, 2019 Filed Jul 29, 2019 16:27 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | Exercise / conversionCommon Stock | 10,000 | $4.62 | $46,200.00 |
DisclosureSEC source: 0001567619-19-015342 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionSeries B Preferred Stock · Derivative | 24,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 10 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 24,101 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionSeries A Preferred Stock · Derivative | 71,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 9 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 71,745 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionSeries B Preferred Stock · Derivative | 578,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 8 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 578,447 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.exercise_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · derivative.expiration_date: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · derivative.underlying_shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionSeries A Preferred Stock · Derivative | 1,721,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · derivative · entry 7 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 0 Underlying: Common Stock · 1,721,898 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.exercise_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · derivative.expiration_date: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · derivative.underlying_shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · derivative.underlying_shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | PurchaseCommon Stock | 10,000 | $10.00 | $100,000.00 |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 6 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 118,521 F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | PurchaseCommon Stock | 240,000 | $10.00 | $2,400,000.00 |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 5 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,844,545 F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionCommon Stock | 24,101 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 4 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 108,521 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionCommon Stock | 71,745 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 3 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 84,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F5 · ownership.nature: The shares are held by 5AM Co-Investors IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionCommon Stock | 578,447 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 2 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,604,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F4 · shares: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F4 · price: Each share of Series B Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
| May 28, 2019 Filed May 28, 2019 21:08 UTC | IDEAYA Biosciences, Inc. IDYA · Entity 4069 | ConversionCommon Stock | 1,721,898 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001567619-19-012281 · doc1.xml · nonDerivative · entry 1 Stone Paul A. · CIK 0001777511 · SVP, General Counsel 10b5-1 filing: Not disclosed Ownership: Indirect · See footnote Disclosed balance after: 2,026,098 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F2 · shares: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F2 · price: Each share of Series A Preferred Stock was automatically converted on a 1-for-1 basis into Common Stock immediately prior to the closing of the Issuer's initial public offering. F1 · balance_after: Reflects a 1-for-10.2564 reverse stock split of the Issuer's outstanding securities effected prior to the effectiveness of the Issuer's S-1 Registration Statement. F3 · ownership.nature: The shares are held by 5AM Ventures IV, L.P. Mr. Stone disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.